{"id":"intracameral-moxifloxacin-0-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Corneal edema"},{"rate":null,"effect":"Anterior chamber inflammation"},{"rate":null,"effect":"Transient vision disturbance"}]},"_chembl":{"chemblId":"CHEMBL1200735","moleculeType":"Small molecule","molecularWeight":"437.90"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Moxifloxacin works by binding to and inhibiting bacterial DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for DNA replication and repair. This leads to rapid bactericidal activity against a broad spectrum of bacteria. When administered intracamerally (directly into the anterior chamber of the eye), it achieves high local concentrations to prevent endophthalmitis following cataract surgery.","oneSentence":"Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in bacteria.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:49:27.828Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prophylaxis of endophthalmitis following cataract surgery"},{"name":"Intracameral antimicrobial prophylaxis in intraocular surgery"}]},"trialDetails":[{"nctId":"NCT03244072","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery","status":"NOT_YET_RECRUITING","sponsor":"Jason Ahee, M.D.","startDate":"2026-06-01","conditions":"Endophthalmitis","enrollment":60000},{"nctId":"NCT06102265","phase":"","title":"Effect Of Reusing the Operative Supplies On Cataract Surgery and Climate Change","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2023-08-01","conditions":"Ophthalmopathy","enrollment":2000},{"nctId":"NCT05741632","phase":"PHASE1","title":"Safety Profile Comparison of Undiluted Intracameral Moxifloxacin vs. Levofloxacin in Cataract Surgery","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2023-02-01","conditions":"Cataract","enrollment":68},{"nctId":"NCT03634852","phase":"PHASE4","title":"A Two Chemoprophylaxis Approaches After Phacoemulsification Surgery","status":"COMPLETED","sponsor":"Suzan A Rattan","startDate":"2016-10-01","conditions":"Endophthalmitis Postoperative","enrollment":1000},{"nctId":"NCT04403334","phase":"PHASE4","title":"Postoperative Safety Outcomes of Intraoperative Intracameral Preservative-Free Moxifloxacin Versus Levofloxacin","status":"COMPLETED","sponsor":"Peregrine Eye and Laser Institute","startDate":"2018-01-02","conditions":"Cataract Senile, Endophthalmitis, Antibiotic Side Effect","enrollment":114}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":25,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Auromox"],"phase":"marketed","status":"active","brandName":"Intracameral Moxifloxacin 0.1%","genericName":"Intracameral Moxifloxacin 0.1%","companyName":"Suzan A Rattan","companyId":"suzan-a-rattan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in bacteria. Used for Prophylaxis of endophthalmitis following cataract surgery, Intracameral antimicrobial prophylaxis in intraocular surgery.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}